The enoyl-acyl carrier protein reductase (InhA) is a well-known anti-TB target involved in the biosynthesis of mycolic acids and is the target of first- and second-line TB drugs, isoniazid, and ethionamide respectively. The gene discussed is INHA; the disease is tuberculosis.